Studies have reported that KRAS mutation, NDRG4 and BMP3 methylation, and immunoassay fecal immunochemical test (FIT) can be used as important biomarkers for early detection of CRC and precancerous lesions [15–17]. This evidence concerns the gene KRAS and colorectal carcinoma.